Disease · MONDO_0002009
major depressive disorder
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. major depressive disorder. Diseases, record MONDO_0002009. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002009
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
DEPRESSIVE DIS, DEPRESSIVE DIS MAJOR, Depression, Depression, Emotional, Depression, Endogenous, Depression, Involutional, Depression, Neurotic, Depression, Unipolar, Depressions, Depressions, Emotional, Depressions, Endogenous, Depressions, Neurotic, Depressions, Unipolar, Depressive Disorder, Depressive Disorder, Major, Depressive Disorders, Depressive Disorders, Major, Depressive Neuroses, Depressive Neurosis, Depressive Symptom, Depressive Symptoms, Depressive Syndrome, Depressive Syndromes, Disorder, Depressive, Disorder, Major Depressive, Disorders, Depressive, Disorders, Major Depressive, Emotional Depression, Emotional Depressions, Endogenous Depression, Endogenous Depressions, Involutional Depression, Involutional Psychoses, Involutional Psychosis, MAJOR DEPRESSIVE DIS, MDD, Major Depressive Disorders, Neuroses, Depressive, Neurosis, Depressive, Neurotic Depression, Neurotic Depressions, Paraphrenia, Involutional, Psychoses, Involutional, Psychosis, Involutional, Symptom, Depressive, Symptoms, Depressive, Syndrome, Depressive, Syndromes, Depressive, Unipolar Depressions, major depression, major depressive disorder and accelerated response to antidepressant drug treatment, major depressive disorder, response to citalopram therapy in, unipolar depression, unipolar depression, susceptibility to
- Open Targets
- Highest stage of its drugs
- Approval, for 115 of its 472 drugs, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs472
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ESCITALOPRAM | CHEMBL1508 | Small molecule | Approval | ATC and TTD | 157 | 155 | 155 | Drugs and targets |
| SERTRALINE | CHEMBL809 | Small molecule | Approval | ATC and TTD | 103 | 101 | 101 | Drugs and targets |
| DULOXETINE | CHEMBL1175 | Small molecule | Approval | ATC, EMA Human Drugs and TTD | 84 | 76 | 76 | Drugs and targets |
| FLUOXETINE | CHEMBL41 | Small molecule | Approval | ATC and TTD | 75 | 72 | 72 | Drugs and targets |
| VORTIOXETINE | CHEMBL2104993 | Small molecule | Approval | ATC, EMA Human Drugs and TTD | 63 | 60 | 60 | Drugs and targets |
| CITALOPRAM | CHEMBL549 | Small molecule | Approval | ATC and TTD | 54 | 52 | 52 | Drugs and targets |
| ESKETAMINE | CHEMBL395091 | Small molecule | Approval | ATC and ClinicalTrials.gov | 52 | 50 | 50 | Drugs and targets |
| VENLAFAXINE | CHEMBL637 | Small molecule | Approval | ATC and TTD | 50 | 48 | 48 | Drugs and targets |
| PAROXETINE | CHEMBL490 | Small molecule | Approval | ATC and TTD | 45 | 43 | 43 | Drugs and targets |
| BUPROPION | CHEMBL894 | Small molecule | Approval | ATC | 41 | 39 | 38 | Drugs and targets |
1 to 10 of 472
See all 472 drugsTargets336
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A4 | Monoamine transporter | 49 | Monoamine transporter inhibitor; Serotonin transporter antagonist; Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent | Approval | https://conductscience.org/library/genes/6532 | Drugs and targets |
| SLC6A2 | Monoamine transporter | 47 | Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | Approval | https://conductscience.org/library/genes/6530 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 27 | Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist | Approval | https://conductscience.org/library/genes/3356 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 23 | D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D1 and D2 receptor agonist; Dopamine D1 and D2 receptor antagonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator; Dopamine D2 receptor partial agonist; Dopamine receptor antagonist; Dopamine receptors; D2 & D3 antagonist | Approval | https://conductscience.org/library/genes/1813 | Drugs and targets |
| GABRA1 | GABA A receptor alpha-1/beta-1/gamma-2 | 17 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA receptor alpha-1 subunit positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Approval | https://conductscience.org/library/genes/2554 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 17 | Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | Approval | https://conductscience.org/library/genes/3358 | Drugs and targets |
| SLC6A3 | Monoamine transporter | 17 | Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor; Sodium-dependent dopamine transporter releasing agent | Approval | https://conductscience.org/library/genes/6531 | Drugs and targets |
| GABRB1 | GABA A receptor alpha-1/beta-1/gamma-2 | 16 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Approval | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRG2 | GABA A receptor alpha-1/beta-1/gamma-2 | 16 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Approval | https://conductscience.org/library/genes/2566 | Drugs and targets |
| HTR1A | 5-hydroxytryptamine receptor 1A | 16 | Serotonin (5-HT) receptor antagonist; Serotonin 1a (5-HT1a) receptor agonist; Serotonin 1a (5-HT1a) receptor antagonist; Serotonin 1a (5-HT1a) receptor partial agonist | Approval | https://conductscience.org/library/genes/3350 | Drugs and targets |
1 to 10 of 336
See all 336 targetsTrials1,484
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 57 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04446039 | Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea | 370,212 | 2024-12-09 | Major Depression | BUPROPION, DESVENLAFAXINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, TIANEPTINE, VENLAFAXINE, VORTIOXETINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05932407 | A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression | 147,777 | 2025-03-03 | Major Depressive Disorder | VORTIOXETINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02775864 | Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia | 81,921 | 2019-06-07 | Schizophrenia, Schizoaffective Disorder | BENZODIAZEPINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01360866 | Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | Phase 3 | 2,944 | 2018-09-17 | Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders | BREXPIPRAZOLE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, VENLAFAXINE | Its record names the disease | ClinicalTrials.gov |
| NCT01153347 | A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder | Phase 3 | 2,409 | 2012-11-20 | Major Depressive Disorder, Depression | DEXMECAMYLAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT01727726 | A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial | Phase 3 | 2,182 | 2018-06-08 | Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT03466346 | SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project | Not applicable | 2,162 | 2025-12-02 | Depression, Unipolar, Posttraumatic Stress Disorder, Trauma | FLUOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT01838681 | Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment | Phase 3 | 1,986 | 2017-08-09 | Major Depressive Disorder | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01436175 | SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study | Phase 3 | 1,570 | 2015-02-23 | Major Depressive Disorder | LISDEXAMFETAMINE DIMESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT01360632 | Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial) | Phase 3 | 1,539 | 2016-01-01 | Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 1,484
See all 1,484 trialsComparisons in its trials381
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vortioxetine Treatment vs SSRI Treatment: Number of Participants Who Experienced of Intracranial Hemorrhage in Total Follow-up Period | 2 of 22,827 | 25 of 124,950 | 147,777 | NCT05932407 | Trial comparisons |
| FSC Cohort vs AC Cohort: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation | 200 of 1,078 | 674 of 2,923 | 4,001 | NCT01337336 | Trial comparisons |
| LY2216684 + SSRI Open-Label Phase vs Discontinuation Phase: serious adverse events | 13 of 600 | 0 of 472 | 1,072 | NCT01155661 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Full Functional Remission During the Randomised Treatment Period | 73 of 441 | 68 of 444 | 885 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Full Remission Sustained During the Randomised Treatment Period | 105 of 441 | 84 of 444 | 885 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Full Global Score Remission During the Randomised Treatment Period | 143 of 441 | 121 of 444 | 885 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Full Remission During the Randomised Treatment Period | 110 of 441 | 95 of 444 | 885 | NCT01838681 | Trial comparisons |
| Placebo and ADT vs Brexpiprazole and ADT: serious adverse events | 13 of 441 | 9 of 444 | 885 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Response at Week 6 During the Randomised Treatment Period | 76 of 440 | 82 of 442 | 882 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Remission at Week 24 in the Randomised Treatment Period | 198 of 440 | 176 of 442 | 882 | NCT01838681 | Trial comparisons |
1 to 10 of 381
See all 381 comparisons in its trialsPapers from its trials1,249
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002009
GET https://conductscience.org/api/diseases/v1/MONDO_0002009/drugs?page=2